The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Teriparatide [rhPTH(1–34)] increases bone mineral density and reduces the risk of vertebral fracture in women. We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 μg, or teriparatide 40 μg. All subjects also received supplemental calcium and vitamin D. The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies. Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity. Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 μg) and 9.0% (40 μg) above baseline (p < 0.001 vs. placebo for both comparisons). Femoral neck bone mineral density increased 1.5% (20 μg; p = 0.029) and 2.9% (40 μg; p < 0.001), and whole body bone mineral content increased 0.6% (20 μg; p = 0.021) and 0.9% (40 μg; p = 0.005) above baseline in the teriparatide subjects. There was no change in radial bone mineral density in the teriparatide groups. Bone mineral density responses to teriparatide were similar regardless of gonadal status, age, baseline bone mineral density, body mass index, smoking, or alcohol intake. Subjects experienced expected changes in mineral metabolism. Adverse events were similar in the placebo and 20-μg groups, but more frequent in the 40-μg group. This study shows that teriparatide treatment results in an increase in bone mineral density and is a potentially useful therapy for osteoporosis in men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationWorld-wide Projections for Hip Fracture
Gullberg, B., Johnell, O., & Kanis, J. A. (1997) · Osteoporosis International · doi:10.1007/pl00004148 · Cited by 2,285
Cooper, C., Atkinson, E. J., MichaelO'Fallon, W., & Dr. Melton, J. L. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070214 · Cited by 1,528
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Self-citationO'Neill, T. W., Felsenberg, D., Varlow, J., Cooper, C., Kanis, J. A., Silman, A. J., & The European Vertebral Osteoporosis Study Group (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110719 · Cited by 960
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Self-citationVahle, J. L., Sato, M., Long, G. G., Young, J. K., Francis, P. C., Engelhardt, J. A., Westmore, M. S., Ma, Y. L., & Nold, J. B. (2002) · Toxicologic Pathology · doi:10.1080/01926230252929882 · Cited by 695
Vertebral Fractures Predict Subsequent Fractures
Melton III, L. J., Atkinson, E. J., Cooper, C., O'Fallon, W. M., & Riggs, B. L. (1999) · Osteoporosis International · doi:10.1007/s001980050218 · Cited by 501
Khosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Cited by
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Self-citationKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Self-citationThe Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J. A., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 826
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Self-citationDrug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.7498 · Cited by 665
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
Self-citationHodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Harris, D. W., Conrad Johnston, C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 605
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
“OP (10) and increased BMD in men with hypogonadal or idiopathic OP (11).”
BackgroundOpposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1762 · Cited by 444
Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00307 · Cited by 436
“A single primary prevention trial of parathyroid hormone reported a non–statistically significant trend toward a reduction in vertebral and nonvertebral fractures (11).”
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., Miyauchi, A., Maddox, J., Chen, L., & Horlait, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02163 · Cited by 328
Kaufman, J.-M., Orwoll, E., Goemaere, S., San Martin, J., Hossain, A., Dalsky, G. P., Lindsay, R., & Mitlak, B. H. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1713-3 · Cited by 320
Self-citationChen, P., Satterwhite, J. H., Licata, A. A., Lewiecki, E. M., Sipos, A. A., Misurski, D. M., & Wagman, R. B. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050105 · Cited by 311
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors
Gensure, R. C., Gardella, T. J., & Jüppner, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.069 · Cited by 301
Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080506 · Cited by 290
Murad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., Abu Elnour, N. O., Erwin, P. J., Hazem, A., Puhan, M. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3060 · Cited by 277
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Guidelines for the diagnosis, prevention and management of osteoporosis
Rossini, M., Adami, S., Bertoldo, F., Diacinti, D., Gatti, D., Giannini, S., Giusti, A., Malavolta, N., Minisola, S., Osella, G., et al. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.870 · Cited by 272
Self-citationNakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Finkelstein, J. S., Wyland, J. J., Lee, H., & Neer, R. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1703 · Cited by 265
Boonen, S., Marin, F., Obermayer-Pietsch, B., Simões, M. E., Barker, C., Glass, E. V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0711 · Cited by 252
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
“The evidence related to teriparatide preventing nonvertebral fractures is mixed; 1 large randomized trial showed a reduction in nonvertebral fractures (34) but 2 small trials did not (87, 88).”
BackgroundGlucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
(2005) · PubMed · Cited by 135
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
Self-citationWang, N., Gao, J., Jia, M., Ma, X., Lei, Z., Da, F., Yan, F., Zhang, H., Zhou, Y., Li, M., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485776 · Cited by 42
Metadata
- Authors
- Orwoll, E., Scheele, W., Paul, S., Adami, S., Syversen, U., Diez-Perez, A., Kaufman, J.-M., Clancy, A., & Gaich, G.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 9-17
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2083011022
- Cited by
- 776
- References
- 25
- FWCI
- 48.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.